Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

220 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Günther M, et al. Eur J Pharm Biopharm. 2011 Apr;77(3):438-49. doi: 10.1016/j.ejpb.2010.11.007. Epub 2010 Nov 18. Eur J Pharm Biopharm. 2011. PMID: 21093588 Review.
RNA interference (RNAi) is a promising strategy to inhibit the expression of pathologically relevant genes, which show aberrant (over-)expression, e.g. in tumors or other pathologies. ...This review article gives a comprehensive overview of pre-clinical in vivo stud …
RNA interference (RNAi) is a promising strategy to inhibit the expression of pathologically relevant genes, which show aberrant (over …
The proto-oncogene Pim-1 is a target of miR-33a.
Thomas M, Lange-Grünweller K, Weirauch U, Gutsch D, Aigner A, Grünweller A, Hartmann RK. Thomas M, et al. Oncogene. 2012 Feb 16;31(7):918-28. doi: 10.1038/onc.2011.278. Epub 2011 Jul 11. Oncogene. 2012. PMID: 21743487
So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miRNA with potential tumor suppressor activity, acting through inhibition of Pim-1. ...In conclusion, we demonstrate the potential of miR-33a t …
So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miR …
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. Urban-Klein B, et al. Gene Ther. 2005 Mar;12(5):461-6. doi: 10.1038/sj.gt.3302425. Gene Ther. 2005. PMID: 15616603
The i.p. injection of PEI-complexed, but not of naked siRNAs targeting the c-erbB2/neu (HER-2) receptor results in a marked reduction of tumor growth through siRNA-mediated HER-2 downregulation. Hence, we establish a novel and simple system for the systemic in vivo …
The i.p. injection of PEI-complexed, but not of naked siRNAs targeting the c-erbB2/neu (HER-2) receptor results in a marked reduction …
Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression.
Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F. Aigner A, et al. Gene Ther. 2002 Dec;9(24):1700-7. doi: 10.1038/sj.gt.3301839. Gene Ther. 2002. PMID: 12457284
In this paper, we present a method for protection and cellular delivery of ribozymes by complexation with a low molecular weight polyethylenimine (LMW-PEI). ...Thus, this paper describes a novel method for exogenous delivery of any bioactive RNA ribozyme in v …
In this paper, we present a method for protection and cellular delivery of ribozymes by complexation with a low molecular weig …
Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients.
Jäger R, List B, Knabbe C, Souttou B, Raulais D, Zeiler T, Wellstein A, Aigner A, Neubauer A, Zugmaier G. Jäger R, et al. Br J Cancer. 2002 Mar 18;86(6):858-63. doi: 10.1038/sj.bjc.6600202. Br J Cancer. 2002. PMID: 11953815 Free PMC article.
Pleiotrophin is a heparin-binding growth factor involved in the differentiation and proliferation of neuronal tissue during embryogenesis, and also secreted by melanoma and breast carcinoma cells. ...Using a specific ELISA-test we studied patients with small cell lu …
Pleiotrophin is a heparin-binding growth factor involved in the differentiation and proliferation of neuronal tissue during embryogen …
Cellular delivery in vivo of siRNA-based therapeutics.
Aigner A. Aigner A. Curr Pharm Des. 2008;14(34):3603-19. doi: 10.2174/138161208786898815. Curr Pharm Des. 2008. PMID: 19075737 Review.
RNAi interference (RNAi) is an almost standard method for the knockdown of any target gene of interest in vitro, exploring a naturally occurring catalytic mechanism. ...It gives a comprehensive overview including a detailed listing of in vivo studies which ha …
RNAi interference (RNAi) is an almost standard method for the knockdown of any target gene of interest in vitro, exploring a naturall …
CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer.
Ripka S, Neesse A, Riedel J, Bug E, Aigner A, Poulsom R, Fulda S, Neoptolemos J, Greenhalf W, Barth P, Gress TM, Michl P. Ripka S, et al. Gut. 2010 Aug;59(8):1101-10. doi: 10.1136/gut.2009.189720. Epub 2010 May 4. Gut. 2010. PMID: 20442202
BACKGROUND AND AIMS: The transcription factor CUX1 is known as a regulator of cell differentiation and cell cycle progression. ...The effect of CUX1 knock-down by nanoparticle-complexed small interfering RNA (siRNA) in vivo was analysed in a murine xenograft model. …
BACKGROUND AND AIMS: The transcription factor CUX1 is known as a regulator of cell differentiation and cell cycle progression. ...The …
Sustained delivery of siRNA poly- and lipopolyplexes from porous macromer-crosslinked gelatin gels.
Schwabe K, Ewe A, Kohn C, Loth T, Aigner A, Hacker MC, Schulz-Siegmund M. Schwabe K, et al. Int J Pharm. 2017 Jun 30;526(1-2):178-187. doi: 10.1016/j.ijpharm.2017.04.065. Epub 2017 Apr 27. Int J Pharm. 2017. PMID: 28456652
RNA interference (RNAi) is a promising technique to treat severe diseases on a pre-protein level. We and others postulate that the release of nanoparticle-complexed small interfering RNA (siRNA) from implanted biomaterials could provide structural support for tissue …
RNA interference (RNAi) is a promising technique to treat severe diseases on a pre-protein level. We and others postulate that …
Tumor tissue slice cultures as a platform for analyzing tissue-penetration and biological activities of nanoparticles.
Merz L, Höbel S, Kallendrusch S, Ewe A, Bechmann I, Franke H, Merz F, Aigner A. Merz L, et al. Eur J Pharm Biopharm. 2017 Mar;112:45-50. doi: 10.1016/j.ejpb.2016.11.013. Epub 2016 Nov 15. Eur J Pharm Biopharm. 2017. PMID: 27864052
The success of therapeutic nanoparticles depends, among others, on their ability to penetrate a tissue for actually reaching the target cells, and their efficient cellular uptake in the context of intact tissue and stroma. ...As a model system, we employ 350μm thick …
The success of therapeutic nanoparticles depends, among others, on their ability to penetrate a tissue for actually reaching the targ …
220 results
Jump to page
Feedback